{"id":30634,"date":"2025-05-29T14:59:03","date_gmt":"2025-05-29T04:59:03","guid":{"rendered":"https:\/\/template.reachmarkets.com.au\/investorportal\/?p=30634"},"modified":"2025-05-29T15:18:48","modified_gmt":"2025-05-29T05:18:48","slug":"investor-briefing-with-james-mcdonnell","status":"publish","type":"post","link":"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing-with-james-mcdonnell\/","title":{"rendered":"Investor Briefing with James McDonnell"},"content":{"rendered":"\n<section id=\"investor-briefing\" class=\"wp-block-gutentor-m3 section-gm389969a gutentor-module gutentor-container-cover has-image-bg has-custom-bg\"><div class=\"grid-container\">\n<section id=\"gm0f6be90\" class=\"wp-block-gutentor-m4 section-gm0f6be90 gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gm7c5eff\" class=\"wp-block-gutentor-m4-col col-gm7c5eff gutentor-single-column  grid-lg-12 grid-md-12 grid-12\"><div id=\"section-gm7c5eff\" class=\"section-gm7c5eff gutentor-col-wrap\">\n<h2 class=\"wp-block-heading has-text-align-center has-white-color has-text-color\" style=\"font-size:33px\">Prescient Therapeutics: Shareholder Briefing with CEO James McDonnell<\/h2>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<section id=\"gm6aed5a6\" class=\"wp-block-gutentor-m4 section-gm6aed5a6 gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gmdeb126\" class=\"wp-block-gutentor-m4-col col-gmdeb126 gutentor-single-column  grid-lg-7 grid-md-6 grid-12\"><div id=\"section-gmdeb126\" class=\"section-gmdeb126 gutentor-col-wrap\">\n<figure class=\"wp-block-image size-full showvi\"><img loading=\"lazy\" decoding=\"async\" width=\"650\" height=\"360\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/PTX-QA-3.png\" alt=\"\" class=\"wp-image-30326\" srcset=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/PTX-QA-3.png 650w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/PTX-QA-3-300x166.png 300w\" sizes=\"auto, (max-width: 650px) 100vw, 650px\" \/><\/figure>\n\n\n\n<script src=\"https:\/\/ajax.googleapis.com\/ajax\/libs\/jquery\/3.5.1\/jquery.min.js\"><\/script>\n<script type=\"text\/javascript\"> \njQuery(document).ready(function ($) {\n    $('.showvi').click(function(e) {\n    e.preventDefault();\n  $('.showvi').html('<iframe loading=\"lazy\" src=\"https:\/\/player.vimeo.com\/video\/1088633513?title=0&#038;byline=0&#038;portrait=0\" width=\"100%\" height=\"410\" frameborder=\"0\" allow=\"autoplay; fullscreen\" allowfullscreen><\/iframe>');\n});\n});\n\n <\/script>\n<script type=\"text\/javascript\">jQuery(document).ready(function($){\n    $(\".showvi\").append(\"<img class='play-icon play-video' src='https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/playvideo-3-1.svg' \/>\");\n});<\/script>\n<\/div><\/div>\n\n\n\n<div id=\"col-gm2d899d\" class=\"wp-block-gutentor-m4-col col-gm2d899d gutentor-single-column  grid-lg-5 grid-md-6 grid-12 homepage-custom\"><div id=\"section-gm2d899d\" class=\"section-gm2d899d gutentor-col-wrap\">\n<p class=\"has-white-color has-text-color\">CEO James McDonnell, held a shareholder briefing with Reach Markets.<\/p>\n\n\n\n<p class=\"has-white-color has-text-color\">In this session, James discussed:<\/p>\n\n\n\n<ul class=\"wp-block-list white\">\n<li>Why the First Patient Dosed marks a significant milestone in the commencement of the PTX-100 Phase 2a study, bringing a potential treatment one step closer to a current unmet need.<\/li>\n\n\n\n<li>How the FDA\u2019s Fast Track and Orphan Drug Designations could lead to accelerated approval for PTX-100 and progress commercialisation \u2013 with a A$1bn+ market in the US alone.<\/li>\n\n\n\n<li>Why PTX-100 is just one application of Prescient\u2019s much broader RAS Family inhibitor technology, which has potential applications for 22% of cancer cases world-wide.<\/li>\n<\/ul>\n\n\n\n<p><\/p>\n\n\n\n<p class=\"has-white-color has-text-color\">Recorded on 29th May 2025 at 12pm (AEST)<\/p>\n\n\n\n<p><a href=\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing\/\">Join the next Prescient Therapeutics webcast<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/template.reachmarkets.com.au\/investorportal\/register\/\">Register to stay up to date with Prescient Therapeutics<\/a><\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<section id=\"bio\" class=\"wp-block-gutentor-m3 alignwide section-gm64aeaf8 gutentor-module gutentor-container-cover custom-fullwidth\"><div class=\"grid-container\">\n<h4 class=\"wp-block-heading speak has-text-color\" style=\"color:#ffcc00\">Featured Speaker<\/h4>\n\n\n\n<h3 class=\"wp-block-heading has-text-align-center speaker-heading has-white-color has-text-color\"><\/h3>\n\n\n\n<section id=\"gma633b86\" class=\"wp-block-gutentor-m4 section-gma633b86 gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gm2cc70c\" class=\"wp-block-gutentor-m4-col col-gm2cc70c gutentor-single-column  grid-lg-3 grid-md-12 grid-12\"><div id=\"section-gm2cc70c\" class=\"section-gm2cc70c gutentor-col-wrap\"><\/div><\/div>\n\n\n\n<div id=\"col-gm5db929\" class=\"wp-block-gutentor-m4-col col-gm5db929 gutentor-single-column  grid-lg-6 grid-md-12 grid-12\"><div id=\"section-gm5db929\" class=\"section-gm5db929 gutentor-col-wrap\">\n<figure class=\"wp-block-image size-full speaker-img\"><img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/James_McDonnell_PTX.png\" alt=\"\" class=\"wp-image-30282\" srcset=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/James_McDonnell_PTX.png 300w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/James_McDonnell_PTX-150x150.png 150w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/figure>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading has-text-align-center speaker-heading has-white-color has-text-color\">James McDonnell<\/h3>\n\n\n\n<h4 class=\"wp-block-heading has-text-align-center speaker-title has-white-color has-text-color\">CEO<\/h4>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-text-align-center speaker-bio has-white-color has-text-color\">James McDonnell is a seasoned leader in the biopharmaceutical industry, bringing over 25 years of global experience in pharmaceuticals, with a particular focus on blood disorders and hematological malignancies such as Myeloma, Myelodysplasia, and CML. <\/p>\n\n\n\n<p class=\"has-text-align-center speaker-bio has-white-color has-text-color\">Throughout his career, James has held senior leadership roles at renowned pharmaceutical companies, including Pharmion and CSL Vifor. At Pharmion, he spearheaded the growth of its oncology and hematology portfolio as Head of Global Marketing, contributing to the company&#8217;s acquistion by Celgene Corporation for US$2.9 billion. Most recently, James served as Global Commercial Lead for Patient Blood Management at CSL Vifor, where he drove key enterprise-wide strategic initiatives.<\/p>\n\n\n\n<p class=\"has-text-align-center speaker-bio has-white-color has-text-color\">James is a registered pharmacist and a member of the Royal Pharmaceutical Society. He holds a Graduate Diploma in Marketing from Monash University and is a graduate of the Australian Institute of Company Directors.<\/p>\n<\/div><\/div>\n\n\n\n<div id=\"col-gm58cc51\" class=\"wp-block-gutentor-m4-col col-gm58cc51 gutentor-single-column  grid-lg-3 grid-md-12 grid-12\"><div id=\"section-gm58cc51\" class=\"section-gm58cc51 gutentor-col-wrap\">\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading has-text-align-center speaker-heading has-white-color has-text-color\"><\/h3>\n<\/div><\/div>\n<\/div><\/div><\/section>\n<\/div><\/section>\n<\/div><\/section>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":38,"featured_media":30326,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,6],"tags":[29],"class_list":["post-30634","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-video","tag-prescient-therapeutics"],"gutentor_comment":0,"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Investor Briefing with James McDonnell - PTX Therapeutics<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Investor Briefing with James McDonnell - PTX Therapeutics\" \/>\n<meta property=\"og:url\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing-with-james-mcdonnell\/\" \/>\n<meta property=\"og:site_name\" content=\"PTX Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-29T04:59:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-29T05:18:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/PTX-QA-3.png\" \/>\n\t<meta property=\"og:image:width\" content=\"650\" \/>\n\t<meta property=\"og:image:height\" content=\"360\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Adrian Montesano\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Adrian Montesano\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing-with-james-mcdonnell\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing-with-james-mcdonnell\/\"},\"author\":{\"name\":\"Adrian Montesano\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/77eeea3f70b4075df3b2207ba88cc5b6\"},\"headline\":\"Investor Briefing with James McDonnell\",\"datePublished\":\"2025-05-29T04:59:03+00:00\",\"dateModified\":\"2025-05-29T05:18:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing-with-james-mcdonnell\/\"},\"wordCount\":275,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing-with-james-mcdonnell\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/PTX-QA-3.png\",\"keywords\":[\"Prescient Therapeutics\"],\"articleSection\":[\"News\",\"Video\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing-with-james-mcdonnell\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing-with-james-mcdonnell\/\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing-with-james-mcdonnell\/\",\"name\":\"Investor Briefing with James McDonnell - PTX Therapeutics\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing-with-james-mcdonnell\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing-with-james-mcdonnell\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/PTX-QA-3.png\",\"datePublished\":\"2025-05-29T04:59:03+00:00\",\"dateModified\":\"2025-05-29T05:18:48+00:00\",\"author\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/77eeea3f70b4075df3b2207ba88cc5b6\"},\"breadcrumb\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing-with-james-mcdonnell\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing-with-james-mcdonnell\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing-with-james-mcdonnell\/#primaryimage\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/PTX-QA-3.png\",\"contentUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/PTX-QA-3.png\",\"width\":650,\"height\":360},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing-with-james-mcdonnell\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investor Briefing with James McDonnell\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\",\"name\":\"PTX Therapeutics\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/77eeea3f70b4075df3b2207ba88cc5b6\",\"name\":\"Adrian Montesano\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/d23955e73043fde98cb92bd29b69f088f6103da014084b9f3e2fffa65e5558ea?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d23955e73043fde98cb92bd29b69f088f6103da014084b9f3e2fffa65e5558ea?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d23955e73043fde98cb92bd29b69f088f6103da014084b9f3e2fffa65e5558ea?s=96&d=mm&r=g\",\"caption\":\"Adrian Montesano\"},\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/author\/adrian-montesano\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Investor Briefing with James McDonnell - PTX Therapeutics","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Investor Briefing with James McDonnell - PTX Therapeutics","og_url":"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing-with-james-mcdonnell\/","og_site_name":"PTX Therapeutics","article_published_time":"2025-05-29T04:59:03+00:00","article_modified_time":"2025-05-29T05:18:48+00:00","og_image":[{"width":650,"height":360,"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/PTX-QA-3.png","type":"image\/png"}],"author":"Adrian Montesano","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Adrian Montesano","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing-with-james-mcdonnell\/#article","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing-with-james-mcdonnell\/"},"author":{"name":"Adrian Montesano","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/77eeea3f70b4075df3b2207ba88cc5b6"},"headline":"Investor Briefing with James McDonnell","datePublished":"2025-05-29T04:59:03+00:00","dateModified":"2025-05-29T05:18:48+00:00","mainEntityOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing-with-james-mcdonnell\/"},"wordCount":275,"commentCount":0,"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing-with-james-mcdonnell\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/PTX-QA-3.png","keywords":["Prescient Therapeutics"],"articleSection":["News","Video"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing-with-james-mcdonnell\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing-with-james-mcdonnell\/","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing-with-james-mcdonnell\/","name":"Investor Briefing with James McDonnell - PTX Therapeutics","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website"},"primaryImageOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing-with-james-mcdonnell\/#primaryimage"},"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing-with-james-mcdonnell\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/PTX-QA-3.png","datePublished":"2025-05-29T04:59:03+00:00","dateModified":"2025-05-29T05:18:48+00:00","author":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/77eeea3f70b4075df3b2207ba88cc5b6"},"breadcrumb":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing-with-james-mcdonnell\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing-with-james-mcdonnell\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing-with-james-mcdonnell\/#primaryimage","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/PTX-QA-3.png","contentUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/PTX-QA-3.png","width":650,"height":360},{"@type":"BreadcrumbList","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing-with-james-mcdonnell\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/template.reachmarkets.com.au\/investorportal\/"},{"@type":"ListItem","position":2,"name":"Investor Briefing with James McDonnell"}]},{"@type":"WebSite","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/","name":"PTX Therapeutics","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/77eeea3f70b4075df3b2207ba88cc5b6","name":"Adrian Montesano","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/d23955e73043fde98cb92bd29b69f088f6103da014084b9f3e2fffa65e5558ea?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/d23955e73043fde98cb92bd29b69f088f6103da014084b9f3e2fffa65e5558ea?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d23955e73043fde98cb92bd29b69f088f6103da014084b9f3e2fffa65e5558ea?s=96&d=mm&r=g","caption":"Adrian Montesano"},"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/author\/adrian-montesano\/"}]}},"_links":{"self":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/30634","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/comments?post=30634"}],"version-history":[{"count":3,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/30634\/revisions"}],"predecessor-version":[{"id":30637,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/30634\/revisions\/30637"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media\/30326"}],"wp:attachment":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media?parent=30634"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/categories?post=30634"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/tags?post=30634"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}